Literature DB >> 25757577

Orexin A-mediated AKT signaling in the dentate gyrus contributes to the acquisition, expression and reinstatement of morphine-induced conditioned place preference.

Sui-Jun Guo1, Yu Cui2, Zhen-Zhen Huang2, Huan Liu2, Xue-Qin Zhang1, Jin-Xiang Jiang1, Wen-Jun Xin2.   

Abstract

Accumulating evidence indicates that the hippocampal dentate gyrus (DG), a critical brain region contributing to learning and memory, is involved in the addiction and relapse to abused drugs. Emerging studies also suggest the role of orexin signaling in the rewarding behavior induced by repeated exposure to opiates. In the present study, we investigated the dynamic adaptation of orexin signaling in the DG and its functional significance in the acquisition, expression, maintenance of and relapse to rewarding behavior induced by morphine. Repeated place conditioning with morphine significantly increased the orexin A content released from the lateral hypothalamic area projecting neurons into the DG. Local infusions of orexin A into the DG sensitized the acquisition of and relapse to the conditioned place preference induced by morphine. The application of the orexin receptor type 1 (OXR1) antagonist SB334867 significantly abolished the acquisition, expression and maintenance of the conditioned place preference induced by repeated exposure to morphine. Furthermore, the significant increase of the phosphorylation of AKT in the DG was associated with preference for the morphine-paired chamber in rats, which was reversed by the local administration of an OXR1 antagonist. Thus, these findings suggested that the dynamic upregulation of orexin A signaling, via the AKT pathway in the DG, may promote the acquisition and maintenance of opioid-induced craving behaviors and may increase sensitivity to the rewarding effect of subsequent opioids.
© 2015 Society for the Study of Addiction.

Entities:  

Keywords:  Morphine; orexin; reward

Mesh:

Substances:

Year:  2015        PMID: 25757577     DOI: 10.1111/adb.12236

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  7 in total

1.  GluR2-3Y Inhibits the Acquisition and Reinstatement of Morphine-Induced Conditioned Place Preference in Rats.

Authors:  Xiao-Jing Lin; Jian-Jun Zhang; Long-Chuan Yu
Journal:  Neurosci Bull       Date:  2016-02-29       Impact factor: 5.203

2.  Nortriptyline Enhances Morphine-Conditioned Place Preference in Neuropathic Rats: Role of the Central Noradrenergic System.

Authors:  Wenli Mi; Shuxing Wang; Zerong You; Grewo Lim; Michael F McCabe; Hyangin Kim; Lucy Chen; Jianren Mao
Journal:  Anesth Analg       Date:  2017-09       Impact factor: 5.108

3.  Image-guided cranial irradiation-induced ablation of dentate gyrus neurogenesis impairs extinction of recent morphine reward memories.

Authors:  Phillip D Rivera; Steven J Simmons; Ryan P Reynolds; Alanna L Just; Shari G Birnbaum; Amelia J Eisch
Journal:  Hippocampus       Date:  2019-02-18       Impact factor: 3.899

Review 4.  Sleep-mediated regulation of reward circuits: implications in substance use disorders.

Authors:  Rong Guo; Dylan Thomas Vaughan; Ana Lourdes Almeida Rojo; Yanhua H Huang
Journal:  Neuropsychopharmacology       Date:  2022-06-16       Impact factor: 7.853

Review 5.  Recent advances in understanding the roles of hypocretin/orexin in arousal, affect, and motivation.

Authors:  Natalie Nevárez; Luis de Lecea
Journal:  F1000Res       Date:  2018-09-06

6.  Generation of silent synapses in dentate gyrus correlates with development of alcohol addiction.

Authors:  Anna Beroun; Maria Nalberczak-Skóra; Zofia Harda; Małgorzata Piechota; Magdalena Ziółkowska; Anna Cały; Roberto Pagano; Kasia Radwanska
Journal:  Neuropsychopharmacology       Date:  2018-06-15       Impact factor: 7.853

7.  Role of Orexin-1 Receptor Within the Ventral Tegmental Area in Mediating Stress- and Morphine Priming-induced Reinstatement of Conditioned Place Preference in Rats.

Authors:  Ronak Azizbeigi; Zahra Farzinpour; Abbas Haghparast
Journal:  Basic Clin Neurosci       Date:  2019-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.